Cellebrite DI Ltd. CLBT
Regular-session close
After hours · Nov 20, 4:26 PM ET
- YTD
- -40.27%
- 1 year
- -38.25%
5D -0.73 (-6.30%)
- Market cap
- 2.71B
- Revenue (ttm)
- 537.28M
- Profit margin
- 12.14%
- EPS (ttm)
- 0.25
- Shares out
- 251.34M
- P/E ratio
- 43.08
- Forward P/E
- 16.09
- YTD return
- -40.27%
- 1-year return
- -38.25%
- 50-day average
- 11.57
- Volume
- 2.71M
- Avg volume
- 2.37M
- Open
- 11.18
- Previous close
- 11.32
- Day's range
- 10.72 – 11.41
- 52-week range
- 9.58 – 19.39
- Beta
- 1.01
- Analysts
- Strong Buy
- Price target
- 15.43 (+43.3%)
- Earnings date
- Feb 10, 2027
Key statistics
- 200-day average
- 13.13
- Enterprise value
- 2.36B
- Price / sales
- 5.04
- Price / book
- 4.64
- Revenue growth
- 18.20%
- Free cash flow
- 131.37M
- Total cash
- 483.87M
- Total debt
- 23.35M
- Return on equity
- 12.70%
- Short % of float
- 3.99%
Fundamental scorecard
15 of 25 checks passed on CLBT’s reported financials
15of 25 checks passed
- Value 3 of 5
- Growth 4 of 5
- Profitability 3 of 5
- Financial health 5 of 5
- Dividend No data
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 14.00
- Target (mean)
- 15.43
- Target (high)
- 20.00
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 10, 2027
Expected Feb 10, 2027. Consensus EPS estimate 0.1728.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2027 | Dec 30, 2026 | 0.18 | — | — | — |
| Nov 12, 2026 | Sep 30, 2026 | 0.09404 | 0.11 | +0.02 | +16.97% |
| Aug 13, 2026 | Jun 30, 2026 | 0.05939 | 0.0257 | -0.03 | -56.73% |
| May 14, 2026 | Mar 31, 2026 | 0.05377 | 0.04 | -0.01 | -25.61% |
| Feb 11, 2026 | Dec 31, 2025 | 0.14 | 0.0867 | -0.05 | -38.07% |
| Nov 12, 2025 | Sep 30, 2025 | 0.09449 | 0.08 | -0.01 | -15.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 15, 2026 | DA Davidson | main | Buy | Buy |
| Aug 14, 2026 | Lake Street | main | Buy | Buy |
| Aug 14, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 14, 2026 | DA Davidson | main | Buy | Buy |
| Aug 14, 2026 | Needham | main | Buy | Buy |
| Aug 6, 2026 | DA Davidson | main | Buy | Buy |
About Cellebrite DI Ltd.
Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime, human trafficking, corporate security, and intellectual property theft, as well as financial crimes, including those involving cryptocurrency. It also offers Inseyets, digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations; Guardian Forensics, an evidence management solution which enables customers to manage their digital forensics workflows, and to store, share and review digital evidence; Guardian Collaborate, a digital evidence sharing tool; and Guardian Investigate, a case management and AI-powered analytics solution. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence and enables actionable insights into a range of crime types; Corellium Falcon for conducting mobile vulnerability research, exploit introspection, and malware analysis; and Corellium Viper for mobile application penetration testing capabilities. Further, the company offers professional services, such as training and certification services, and advanced services. It serves federal, state, and local agencies, as well as corporations and service providers. The company is headquartered in Petah Tikva, Israel.
- Sector
- Technology
- Industry
- Software - Infrastructure
- Country
- Israel
- Website
- cellebrite.com
News
Cellebrite DI (CLBT) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Cellebrite DI (CLBT)
Cellebrite DI: Continuous Innovation Including AI Can Drive Growth
Cellebrite DI Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Cellebrite DI (CLBT) JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $15
Cellebrite DI Lowers FY2026 Sales Guidance from $555.000M-$561.000M to $553.000M-$558.000M vs $556.733M Est
Cellebrite DI Q3 Adj. EPS $0.17 Beats $0.16 Estimate, Sales $149.022M Beat $145.923M Estimate
Cellebrite DI Sees Q4 Sales $145.000M-$150.000M vs $151.451M Est
Your note
Sign in to keep a note on CLBT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARTER DAVID | Chief Financial Officer | Sale | Oct 15, 2026 | 322,085 |
| BAUDOT-TRAJTENBERG NADINE PH.D. | Director | Stock Award(Grant) | Sep 16, 2026 | 50,744 |
| CLAMMER ADAM H | Director | Stock Award(Grant) | Sep 16, 2026 | 14,697,600 |
| DOMNITZ YONATAN | Director | Stock Award(Grant) | Sep 16, 2026 | 86,586 |
| GEE DAVID NICHOLAS | Officer | Sale | Aug 23, 2026 | 135,281 |
| HOGAN THOMAS E | Affiliated Person | Sale | Aug 24, 2026 | 765,249 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| True Wind Capital Management, L.P. | 5.56% | 13,861,007 | 149.28M | Sep 29, 2026 |
| Voss Capital, LP | 5.01% | 12,486,863 | 134.48M | Sep 29, 2026 |
| Pertento Partners LLP | 4.89% | 12,188,963 | 131.28M | Sep 29, 2026 |
| Nomura Holdings Inc. | 3.68% | 9,186,655 | 98.94M | Sep 29, 2026 |
| Phoenix Financial Ltd. | 2.05% | 5,111,006 | 55.05M | Sep 29, 2026 |
| Blackrock Inc. | 1.76% | 4,402,124 | 47.41M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 1.63% | 4,057,763 | 43.70M | Sep 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 0.59% | 1,468,906 | 15.82M | Sep 29, 2026 |
| Central Securities Corporation | 0.52% | 1,300,000 | 14.00M | Jun 29, 2026 |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 0.52% | 1,301,013 | 14.01M | Aug 30, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Venture Fund | 0.46% | 1,139,552 | 12.27M | Sep 29, 2026 |
| Fidelity Advisor Series I-Fidelity Advisor Small Cap Fund | 0.40% | 995,800 | 10.72M | Aug 30, 2026 |
